A phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)

Gynecologic Oncology

Volumn 130, Issue 1, 2013, Pages 31-37

  Cognetti, F ^a   Bagnato, A ^a   Colombo, N ^b   Savarese, A ^a   Scambia, G ^c   Sehouli, J ^d   Wimberger, P ^e   Sorio, R ^f   Harter, P ^g   Mari, E ^h   McIntosh, S ^h   Nathan, F ^h   Pemberton, K ^h   Baumann, K ⁱ  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g KLINIKEN ESSEN MITTE   (Germany)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Advanced; Cancer; Carboplatin paclitaxel; Ovarian; ZD4054; Zibotentan

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; GAMMA GLUTAMYLTRANSFERASE; PACLITAXEL; PLACEBO; ZIBOTENTAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER TOXICITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PLACEBOS; PYRROLIDINES; YOUNG ADULT;

EID: 84879093917     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.004     Document Type: Article

References (33)

1. V. Guarneri, F. Piacentini, E. Barbieri, and P.F. Conte Achievements and unmet needs in the management of advanced ovarian cancer Gynecol Oncol 117 2010 152 158
2. A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2012 1234 1244 [Ref Type: Generic]
3. S.C. Rubin, T.C. Randall, K.A. Armstrong, D.S. Chi, and W.J. Hoskins Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings Obstet Gynecol 93 1999 21 24
4. M.K. Parmar, J.A. Ledermann, N. Colombo, B.A. du, J.F. Delaloye, and G.B. Kristensen Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
5. A. Bagnato, F. Spinella, and L. Rosanò Emerging role of the endothelin axis in ovarian tumor progression Endocr Relat Cancer 12 2005 761 772
6. A. Bagnato, M. Loizidou, B.R. Pflug, J. Curwen, and J. Growcott Role of the endothelin axis and its antagonists in the treatment of cancer Br J Pharmacol 163 2011 220 233
7. E.R. Levin Endothelins N Engl J Med 333 1995 356 363
8. L. Rosanò, V. Di Castro, F. Spinella, M.R. Nicotra, P.G. Natali, and A. Bagnato ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo Mol Cancer Ther 6 2007 2003 2011
9. L. Rosanò, V. Di Castro, F. Spinella, G. Tortora, M.R. Nicotra, and P.G. Natali Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity Cancer Res 67 2007 6351 6359
10. L. Rosano, R. Cianfrocca, F. Spinella, C.V. Di, P.G. Natali, and A. Bagnato Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer Can J Physiol Pharmacol 88 2010 676 681
11. AstraZeneca Global policy: bioethics Available at http://www.astrazeneca. com/Responsibility/Code-policies-standards/Policiesstandards 2011
12. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
13. R.M. Simon, S.M. Steinberg, M. Hamilton, A. Hildesheim, S. Khleif, and L.W. Kwak Clinical trial designs for the early clinical development of therapeutic cancer vaccines J Clin Oncol 19 2001 1848 1854
14. N.D. James, A. Caty, H. Payne, M. Borre, B.A. Zonnenberg, and P. Beuzeboc Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial BJU Int 106 2010 966 973
15. L. Rosano, R. Cianfrocca, F. Spinella, V. Di Castro, M.R. Nicotra, and A. Lucidi Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells Clin Cancer Res 17 2011 2350 2360
16. J. Collins The play of chance Fertil Steril 85 2006 1364 1367
17. G. Milano, J.P. Spano, and B. Leyland-Jones EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality Br J Cancer 99 2008 1 5
18. S. Sale Genetically engineered mouse models of ovarian cancer and their utility in drug discovery Curr Protoc Pharmacol 2009 [Chapter 14:Unit14]
19. M.Y. Fong, and S.S. Kakar Ovarian cancer mouse models: a summary of current models and their limitations J Ovarian Res 2 2009 12
20. K.R. Cho Ovarian cancer update: lessons from morphology, molecules, and mice Arch Pathol Lab Med 133 2009 1775 1781
21. R. Cianfrocca, P. Tocci, F. Spinella, Bagnato A. Di CV, and L. Rosano The endothelin A receptor and epidermal growth factor receptor signaling converge on beta-catenin to promote ovarian cancer metastasis Life Sci 91 2012 550 556
22. J.J. McMurray, J.R. Teerlink, G. Cotter, R.C. Bourge, J.G. Cleland, and G. Jondeau Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials JAMA 298 2007 2009 2019
23. E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, and P.A. Vasey Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse J Clin Oncol 28 2010 3323 3329
24. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
25. A.J. White, R.L. Coleman, D.K. Armstrong, D. Glenn, A. Bicher, and D.A. Richards Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: FInal data from a multicenter phase II study J Clin Oncol 28 Suppl. 15 2010 [abst 5001]
26. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
27. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, and G. Rustin Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N Engl J Med 366 2012 1382 1392
28. I.B. Vergote, J.P. Micha, C.H. Pippitt Jr., G.G. Rao, D.L. Spitz, and N. Reed Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer J Clin Oncol 28 15S 2010 [abst 5013]
29. J. Farley, W. Brady, M. Birrer, H. Lankes, R. Coleman, and M. Morgan A Phase II trial of AZD6244 in women with recurrent low-grade serous carcinoma of the ovary or peritoneum Int J Gynecol Cancer 21 Suppl. 3 2011 [abst 1719]
30. N.D. James, A. Caty, M. Borre, B.A. Zonnenberg, P. Beuzeboc, and T. Morris Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase II trial Eur Urol 55 2009 1112 1123
31. D. George, and J.W. Moul Emerging treatment options for patients with castration-resistant prostate cancer Prostate 72 2012 338 349
32. M.L. Maitland, C. Hudoba, K.L. Snider, and M.J. Ratain Analysis of the yield of phase II combination therapy trials in medical oncology Clin Cancer Res 16 2010 5296 5302
33. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892